Deformation-based morphometry identifies deep brain structures protected by ocrelizumab.

ABSTRACT:

Background

Despite advancements in treatments for multiple sclerosis, insidious disease progression remains an area of unmet medical need, for which atrophy-based biomarkers may help better characterize the progressive biology.

Methods

We developed and applied a method of longitudinal deformation-based morphometry to provide voxel-level assessments of brain volume changes and identified brain regions that were significantly impacted by disease-modifying therapy.

Results

Using brain MRI data from two identically designed pivotal trials of relapsing multiple sclerosis (total N = 1483), we identified multiple deep brain regions, including the thalamus and brainstem, where volume loss over time was reduced by ocrelizumab (p < 0.05), a humanized anti-CD20 + monoclonal anti

SUBMITTER: Song Z 

PROVIDER: S-EPMC8861820 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature